ÂÜÀòÂÒÂ×

Sritama Nath, Ph.D. has a diverse work experience spanning multiple industries and roles. Sritama is currently employed at Vor Bio as the Associate Director of Translational Medicine. In this role, they lead and manages both the Clinical Science and Translational Medicine teams, contributing to the advancement of cell and gene therapy programs. Sritama is responsible for hiring and building remote-first teams and has various responsibilities within their position, such as developing and implementing the Clinical Development Plan, leading the development of clinical trial designs, and gathering competitive intelligence.

Prior to their current position, Sritama worked as an Associate Medical Director at Wunderman Thompson Health and as a Medical Writer at Ashfield, part of UDG Healthcare plc and MedThink Communications. Sritama has also held positions as a Clinical Trial Assistant at MedSource, a Visiting Research Scientist at Duke University, a Postdoctoral Fellow at the University of Michigan Medical School, and a Graduate Research Assistant and Graduate Teaching Assistant at UNC Charlotte.

Sritama's work experience also includes a role as a Research Trainee at Jadavpur University and a Research Scientist in Enzyme R&D at Biocon. Throughout their career, they have demonstrated their expertise through multiple scientific publications and presentations at national and international conferences.

Sritama Nath, Ph.D. obtained a Bachelor of Science (B.Sc.) degree in Microbiology from M. S. Ramaiah Degree College in the years 2001 to 2004. In the years 2004 to 2006, they pursued a Master of Science (M.Sc.) degree in Biochemistry from Sri Bhagawan Mahaveer Jain College. Following this, from 2008 to 2013, they attended the University of North Carolina at Charlotte to obtain a Doctor of Philosophy (Ph.D.) degree in Biology, specializing in Cancer Biology and Tumor Immunology.

In 2015, Sritama Nath acquired a Clinical Trial Research Associate Certification Level 1 from Durham Technical Community College.

In 2017, they participated in the Regulatory Affairs Training Program at Duke University, although the field of study is not specified.